Stockreport

Kiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial

KIROMIC BIOPHARMA INC  (KRBP) 
PDF Scans of this first patient in the second cohort show 8.5% reduction in tumor size HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “ [Read more]